Researchers showed that a protein named FOXO1 plays a critical role in heart damage resulting from treatment with anthracycline chemotherapy drugs. Using a rodent model, they also demonstrated that suppressing FOXO1 through the use of FOXO1 inhibitor drugs could prevent the chemotherapy-induced heart damage. Their discovery opens up possibilities for new treatment strategies to reduce heart damage from cancer treatment, which could help increase the life expectancy of cancer survivors.
Click here for original story, Critical protein in cancer treatment-related heart damage
Source: ScienceDaily